mumps vaccine / Sinovac - LARVOL DELTA

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students (clinicaltrials.gov) - P4 | N=400 | Active, not recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease • Influenza • Mumps • Respiratory Diseases

Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial. (PubMed, PLoS One) - "And most AEFI cases were common adverse reactions (66.67%, 38/57). In total, the live attenuated mumps vaccine evaluated in this trial has a favorable safety profile and can be used for large-scale inoculation."

Journal • P4 data • Infectious Disease • Mumps • Pain

Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old (clinicaltrials.gov) - P=N/A; N=10000; Completed; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

Clinical • New trial • Infectious Disease

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (clinicaltrials.gov) - P3; N=1140; Completed; Sponsor: Sinovac Research and Development Co., Ltd.

Clinical • New P3 trial • Infectious Disease

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine (clinicaltrials.gov) - P4; N=920; Completed; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.; Recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Apr 2021; Trial primary completion date: Jun 2020 ➔ Nov 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine (clinicaltrials.gov) - P4; N=920; Recruiting; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

Clinical • New P4 trial • Gene Therapies • Genetic Disorders • Infectious Disease